当前头孢曲松剂量推荐对多数危重患儿是足够的:群体药代动力学建模与模拟研究结果
该研究在45例危重患儿(0-18岁,中位年龄2.5岁)中采集205份总浓度和43份游离浓度样本,用非线性混合效应模型(NONMEM 7.4.3)建立头孢曲松群体药代动力学模型并进行模拟。最终模型为二室模型,体重作为分布容积和清除率的协变量,基于肌酐的估算肾小球滤过率作为清除率的附加协变量。对典型患者(2.5岁、14 kg、eGFR 80 mL/min/1.73 m²),100 mg/kg每日一次方案对MIC 0.5 mg/L和4×MIC(2 mg/L)的达标率(fT>MIC 100%)分别为96.8%和60.8%;50 mg/kg每日两次方案分别为99.9%和93.4%。作者结论为当前方案对多数危重患儿敏感病原体暴露充分,在eGFR>80 mL/min/1.73 m²或低敏感病原体(MIC≥0.5 mg/L)高流行区可考虑50 mg/kg每日两次以改善达标。
要点
- 危重患儿头孢曲松100 mg/kg每日一次(30分钟输注)对MIC 0.5 mg/L的达标率(fT>MIC 100%)为96.8%,对4×MIC(2 mg/L)降至60.8%。
- 同一典型患者改用50 mg/kg每日两次,对MIC 0.5 mg/L和2 mg/L的达标率分别升至99.9%和93.4%。
- 作者认为在eGFR>80 mL/min/1.73 m²或低敏感病原体(MIC≥0.5 mg/L)高流行区,可考虑50 mg/kg每日两次方案以改善达标。
- 群体药代动力学最终模型为二室模型,体重是分布容积和清除率的协变量,基于肌酐的eGFR是清除率的附加协变量。
- 证据来自45例危重患儿的群体药代动力学建模与模拟,非临床结局研究。
适用人群与场景
- 0-18岁危重患儿,已留置中心静脉或动脉导管,接受静脉头孢曲松100 mg/kg每日一次(30分钟输注)治疗。
诊断标准与关键阈值
- 药代动力学靶目标为游离头孢曲松浓度高于MIC的时间占给药间隔100%(fT>MIC 100%)及游离浓度高于4×MIC的时间占给药间隔100%(fT>4×MIC 100%)。
- 模拟评估的MIC为0.5 mg/L(敏感病原体)和4×MIC即2 mg/L(低敏感病原体)。
- 达标率以概率方式表达:典型患者(2.5岁、14 kg、eGFR 80 mL/min/1.73 m²)100 mg/kg每日一次方案对MIC 0.5 mg/L为96.8%、对2 mg/L为60.8%。
处置流程与药物剂量
- 现行方案:头孢曲松100 mg/kg每日一次,静脉输注30分钟。
- 作者认为在eGFR>80 mL/min/1.73 m²或低敏感病原体(MIC≥0.5 mg/L)高流行区,可考虑头孢曲松50 mg/kg每日两次以改善达标。
研究设计与关键结果
- 研究类型:群体药代动力学建模与模拟研究;45例危重患儿(中位年龄2.5岁,范围0.1-16.7岁),采集205份总浓度样本和43份时间匹配的游离浓度样本。
- 最终模型:二室模型,体重作为分布容积和清除率的协变量,基于肌酐的eGFR作为清除率的附加协变量。
- 典型患者(2.5岁、14 kg、eGFR 80 mL/min/1.73 m²)100 mg/kg每日一次方案:对MIC 0.5 mg/L达标率96.8%,对4×MIC(2 mg/L)达标率60.8%(fT>MIC 100%靶目标)。
- 同一典型患者50 mg/kg每日两次方案:对MIC 0.5 mg/L达标率99.9%,对2 mg/L达标率93.4%。
证据类型、等级与局限
- 证据类型:群体药代动力学建模与模拟研究(基于45例危重患儿的机会性采血样本)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对多数危重患儿,现行100 mg/kg每日一次头孢曲松方案对敏感病原体(MIC 0.5 mg/L)暴露充分(达标率96.8%)。
- 作者认为在eGFR>80 mL/min/1.73 m²或低敏感病原体(MIC≥0.5 mg/L)高流行区,可考虑50 mg/kg每日两次方案以改善达标率(对2 mg/L由60.8%升至93.4%)。
指南或共识出处
- POPSICLE研究(ClinicalTrials.gov NCT03248349,2017年8月14日注册);PERFORM研究(ClinicalTrials.gov NCT03502993,2018年4月19日注册)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: Ceftriaxone is a cornerstone antibiotic for critically ill children with severe infections. Despite its widespread use, information on the pharmacokinetics of ceftriaxone is lacking in this population. We aimed to determine ceftriaxone pharmacokinetics in critically ill children and to propose ceftriaxone dosing guidelines resulting in adequate target attainment using population pharmacokinetic modeling and simulation.
METHODS: Critically ill children (aged 0-18 years) treated with intravenous ceftriaxone (100 mg/kg once daily, infused in 30 minutes) and a central or arterial line in place were eligible. Opportunistic blood sampling for total and unbound ceftriaxone concentrations was used. Population pharmacokinetic analysis was performed using non-linear mixed-effects modeling on NONMEM™ Version 7.4.3. Simulations were performed to select optimal doses using probability of target attainment for two pharmacokinetic targets of the minimum inhibitory concentration (MIC) reflecting the susceptibility of pathogens (f T > MIC 100% and fT > 4 × MIC 100%).
RESULTS: Two hundred and five samples for total and 43 time-matched samples for unbound plasma ceftriaxone concentrations were collected from 45 patients, median age 2.5 (range 0.1-16.7) years. A two-compartment model with bodyweight as the co-variate for volume of distribution and clearance, and creatinine-based estimated glomerular filtration rate as an additional covariate for clearance, best described ceftriaxone pharmacokinetics. For a typical patient (2.5 years, 14 kg) with an estimated glomerular filtration rate of 80 mL/min/1.73 m2, the current 100-mg/kg once-daily dose results in a probability of target attainment of 96.8% and 60.8% for a MIC of 0.5 mg/L and 4 × MIC (2 mg/L), respectively, when using fT > MIC 100% as a target. For a 50-mg/kg twice-daily regimen, the probability of target attainment was 99.9% and 93.4%, respectively.
CONCLUSIONS: The current dosing regimen of ceftriaxone provides adequate exposure for susceptible pathogens in most critically ill children. In patients with an estimated glomerular filtration rate of > 80 mL/min/1.73 m2 or in areas with a high prevalence of less-susceptible pathogens (MIC ≥ 0.5 mg/L), a twice-daily dosing regimen of 50 mg/kg can be considered to improve target attainment.
CLINICAL TRIAL REGISTRATION: POPSICLE study (ClinicalTrials.gov, NCT03248349, registered 14 August, 2017), PERFORM study (ClinicalTrials.gov, NCT03502993, registered 19 April, 2018).
参考来源
- Hartman SJF, Upadhyay PJ, Hagedoorn NN, et al. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. Clin Pharmacokinet. 2021. PMID: 34036552. doi:10.1007/s40262-021-01035-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。